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Herein, we describe recruitment efforts for a trial of lipid-lowering medications in adolescents with type 1 diabetes,
age 12–21 years. Based on our experience, future studies will require multiple centers to enroll a sufficient number
of participants for adequate data to direct dyslipidemia medication treatment guidelines for adolescents with type
1 diabetes.
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(T1D) are at high risk for developing early cardiovascu-
lar disease [1]. Current recommendations to consider
pharmacologic treatment of elevated low-density lipo-
protein cholesterol (LDL-c) are based on limited evi-
dence and extrapolation from data in middle age and
older adults. We proposed a trial of lipid-lowering medi-
cations (simvastatin, a statin, compared to Vytorin, a
combination of simvastatin and ezetimibe, a medication
that blocks cholesterol absorption) in our patients ages
12–21 years with LDL ≥ 130 mg/dl, consistent with
current American Diabetes Association (ADA) guide-
lines. In this study, we hypothesized that simvastatin and
Vytorin would be safe in adolescents with T1D and that
in a two-arm design, Vytorin would lower LDL-c more
than monotherapy with simvastatin at 6 months com-
pared to baseline. In this report, we describe observa-
tions from a trial of lipid-lowering medications in T1D,
age 12–21 years.
In 2004 we ascertained that the Barbara Davis Center
for Childhood Diabetes (BDC) followed 1,528 patients
with T1D age 12–21 years. The SEARCH for Diabetes in
Youth study reported LDL-c >130 mg/dl in 15% of T1D
subjects [2]. Based on these data, we estimated that 229
T1D patients age 12–21 years seen at the BDC would
have LDL-c >130 mg/dl. A randomized, double-blind,
placebo-controlled study of lipid-lowering medica-
tions required 82 enrolled subjects which assumed a* Correspondence: Franziska.Bishop@ucdenver.edu
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reproduction in any medium, provided the or36% participation rate. Inclusion criteria were age
12–21 years with T1D diagnosed by positive islet
autoantibodies or provider diagnosis of T1D, and
LDL-c> 130 mg/dl. Patients with familial hypercho-
lesterolemia, triglycerides> 400 mg/dl, T1D of less
than three-months duration, HbA1c> 9.5%, abnormal
thyroid function, abnormal creatine kinase values, ab-
normal liver function tests (ALT/AST), pregnancy or
potential to become pregnant during the study, and
patients on oral contraceptives were excluded.Findings
We identified 105 potential subjects with clinically mea-
sured LDL-c >130 mg/dl or non-HDL-c >160 mg/dl. Of
these, 42 patients proved to be ineligible (A1c> 9.5%, LDL-
c< 130 mg/dl on a repeat test), 26 declined invitation to a
screening visit, 16 expressed one time interest but were not
able to be scheduled, and 3 were interested but were unable
to improve their glycemic control to be eligible for the
study. Therefore, 18 agreed to be in the study and 17 sub-
jects attended a study screening visit of which 9 were en-
rolled in the study (15.8± 2.8 years, 67% male,
A1c=8.3±1.1%, TC=224±42, HDL-c=51±11, TG=112
±66, LDL-c=151±29 mg/dl, BMI=25.4± 5.0 kg/m2)
(Figure 1). Reasons for poor recruitment included elevated
A1c (>9.5%), improved LDL-c from clinic lipid panels to
screening visit (n=42, 40%), lack of interest in taking a
lipid-lowering medication and/or long distance to travel to
study site (n=21, 20%). A positive result of our study was
improved compliance with lipid screening in our clinicLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Figure 1 Study Recruitment and Participation.
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eligible for, but lacking screening lipids over 2.5 years.
Despite current recommendations for intensified gly-
cemic control, diet, and exercise as initial therapies for
dyslipidemia, some adolescents with T1D will not reach
the LDL-c goal of <100 mg/dl. For these patients, data
are needed on the safety, efficacy, and ultimately the
risk/benefit of dyslipidemia medications initiated in ado-
lescence. We are aware of only one published short-term
clinical trial of dyslipidemia medication in adolescents
with T1D [3], although a Juvenile Diabetes Research
Foundation sponsored trial is on-going in the United
Kingdom [4]. Increased awareness of lipid health and
treatment options in this patient population are needed
as some patients and families required months of delib-
eration before deciding to have the patient take a dyslipi-
demia medication in addition to intensification of
glycemic control, diet, and exercise. Based on our ex-
perience, future studies will require multiple centers to
enroll a sufficient number of participants for adequate
data to direct treatment guidelines for pharmacologic
treatment of dyslipidemia in adolescents with T1D.
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